新型冠状病毒肺炎与糖尿病：目前我们了解多少？
COVID-19 and diabetes: What do we know so far?
机构信息
BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Science, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.
出版信息
Exp Biol Med (Maywood). 2022 Aug;247(15):1330-1334. doi: 10.1177/15353702221108914. Epub 2022 Jul 27.
Coronavirus disease 2019 (COVID-19) management has been challenging for patients with comorbidities. Patients with diabetes and COVID-19, in particular, have shown severe symptoms and rapid progression of the disease. They also have a high mortality rate compared to the non-diabetic population. The high mortality rate is caused in people with diabetes who are in a pro-inflammatory condition; this could worsen COVID-19. In addition, people with diabetes have circulatory issues and COVID-19 infection can lead to further clotting problems. It is critical to understand the mechanisms underlying the adverse clinical outcomes in patients with diabetes and COVID-19. This review discusses various disease conditions contributing to poor prognosis in diabetic COVID-19 patients such as hyperglycemia, insulin resistance, impaired pancreatic function, and production of advanced glycation end products.
2019 年冠状病毒病（COVID-19）的管理对合并症患者具有挑战性。患有糖尿病和 COVID-19 的患者尤其表现出严重的症状和疾病的快速进展。与非糖尿病患者相比，他们的死亡率也很高。糖尿病患者处于促炎状态，这会使死亡率更高；这可能会使 COVID-19 恶化。此外，糖尿病患者存在循环问题，COVID-19 感染可能导致进一步的凝血问题。了解糖尿病和 COVID-19 患者不良临床结局的潜在机制至关重要。本综述讨论了导致糖尿病 COVID-19 患者预后不良的各种疾病状况，如高血糖、胰岛素抵抗、胰腺功能受损和晚期糖基化终产物的产生。
Zotero 插件